KRAS and non-small cell lung carcinoma: Additionally, their NSCLC analysis showed that KRAS/SMARCA4 class 2 co-mutations were associated with worse OS (HR = 2.75; 95% CI: 1.84–4.11; p < 0.001) compared to KRAS/SMARCA4 wild-type tumors.